Mesenchymal stem cell‐derived extracellular vesicles for metabolic syndrome therapy: Assessing efficacy with nuclear magnetic resonance spectroscopy
Cell Biochemistry and Function · 2023
DOI: 10.1002/cbf.3881 ↗At a glance
Übersichtsarbeit in Cell Biochemistry and Function, 2023. Written by Magdalene Tan Mei Ling and 4 co-authors. Institution: Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur, Malaysia. Major MEDLINE topics: Metabolic Syndrome, Extracellular Vesicles, Mesenchymal Stem Cells, Mesenchymal Stem Cell Transplantation. Cited 1 times so far (Crossref); 56 references. Funded by: Universiti Kebangsaan Malaysia.
Abstract (original language)
Metabolic syndrome (MetS) represents a cluster of metabolic abnormalities. The prevalence of MetS has surged, transforming it into a pressing public health concern that could potentially affect around 20%–25% of the global population. As MetS continues its ascent, diverse interventions, pharmacological, nonpharmacological and combined have been deployed. Yet, a comprehensive remedy that fully eradicates MetS symptoms remains elusive, compounded by the risks of polypharmacy's emergence. Acknowledging the imperative to grasp MetS's intricate pathologies, deeper insights for future research and therapy optimisation become paramount. Conventional treatments often target specific syndrome elements. However, a novel approach emerges in mesenchymal stem cell‐derived extracellular vesicles (MSC‐EVs) therapy, promising a holistic shift. MSC‐EVs, tiny membranous vesicles secreted by mesenchymal stem cells, have garnered immense attention for their multifaceted bioactivity and regenerative potential. Their ability to modulate inflammation, enhance tissue repair and regulate metabolic pathways has prompted researchers to explore their therapeutic application in MetS. This review primarily aims to provide an overview of how MSC‐EVs therapy can improve metabolic parameters in subjects with MetS disease and also introduce the usefulness of NMR spectroscopy in assessing the efficacy of MSC‐EVs therapy for treating MetS.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur, Malaysia.
- Department of Pharmaceutical Life Sciences, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur, Malaysia.
- Centre for Tissue Engineering and Regenerative Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
- Department of Chemistry and Biology, Centre for Defense Foundation Studies, Universiti Pertahanan Nasional Malaysia, Kuala Lumpur, Malaysia.
Funding
- Universiti Kebangsaan Malaysia
Cite
APA
Ling, M. T. M., Govindaraju, K., Lokanathan, Y., Abidin, A. Z., & Ibrahim, B. (2023). Mesenchymal stem cell‐derived extracellular vesicles for metabolic syndrome therapy: Assessing efficacy with nuclear magnetic resonance spectroscopy. Cell Biochemistry and Function. https://doi.org/10.1002/cbf.3881
Vancouver
Ling MTM, Govindaraju K, Lokanathan Y, Abidin AZ, Ibrahim B. Mesenchymal stem cell‐derived extracellular vesicles for metabolic syndrome therapy: Assessing efficacy with nuclear magnetic resonance spectroscopy. Cell Biochemistry and Function. 2023. doi:10.1002/cbf.3881
BibTeX
@article{Ling2023,
author = {Ling, Magdalene Tan Mei and Govindaraju, Kayatri and Lokanathan, Yogeswaran and Abidin, Asmaa' Zainal and Ibrahim, Baharudin},
title = {Mesenchymal stem cell‐derived extracellular vesicles for metabolic syndrome therapy: Assessing efficacy with nuclear magnetic resonance spectroscopy},
journal = {Cell Biochemistry and Function},
year = {2023},
doi = {10.1002/cbf.3881}
}
EUVIMED